Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving REGENXBIO Inc. and its officers or directors [1] Group 1: Company Developments - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its investigational gene therapy RGX-111 for treating MPS I due to a case of neoplasm in a participant [3] - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the studies [3] - Following the announcement, REGENXBIO's stock price dropped by $2.40 per share, or 17.9%, closing at $11.01 per share on the same day [3] Group 2: Legal and Investigative Actions - Pomerantz LLP is actively seeking investors of REGENXBIO to contact them regarding the investigation into potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Zenas BioPharma, Inc. and its officers or directors, following disappointing results from a clinical trial that negatively impacted the company's stock price [1][3]. Group 1: Company Overview - Zenas BioPharma, Inc. is a publicly traded company on NASDAQ under the ticker ZBIO [1]. - The company recently announced results from the Phase 3 INDIGO trial of its drug obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [3]. Group 2: Trial Results and Market Reaction - The trial results were characterized as "positive" by Zenas; however, analysts indicated that the drug's efficacy did not meet the necessary threshold for commercial viability [3]. - Following the announcement, Zenas's stock price dropped by $17.89 per share, or 51.86%, closing at $16.61 on January 5, 2026 [3]. - On a subsequent conference call, the CEO expressed disappointment regarding the drug's hazard ratio, which did not meet expectations, leading to an additional stock price decline of $1.41 per share, or 8.49%, closing at $15.20 on January 6, 2026 [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Aquestive Therapeutics, Inc. and its officers and directors [1]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is currently facing scrutiny regarding its New Drug Application (NDA) for Anaphylm, as the FDA has identified deficiencies that prevent further discussions on labeling and post-marketing commitments [3]. - Following the announcement of the FDA's findings, Aquestive's stock price experienced a significant decline, falling by $2.30 per share, or 37.04%, closing at $3.91 per share on January 9, 2026 [3]. Group 2: Legal Investigation - Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, is leading the investigation into the claims against Aquestive [1][4]. - The firm has a long history of advocating for victims of securities fraud and has successfully recovered multimillion-dollar damages for class members [4].

Core Viewpoint - PDD Holdings Inc. is under investigation for potential securities fraud and unlawful business practices, following a broader probe initiated by the Chinese government involving over 100 regulators [3]. Group 1: Investigation Details - The investigation by the Chinese government includes allegations of misconduct such as fraudulent deliveries and taxation issues [3]. - The probe was partially triggered by an incident of physical violence between PDD employees and inspectors from the State Administration for Market Regulation (SAMR) [3]. Group 2: Market Reaction - Following the news of the investigation, PDD's American Depositary Receipt (ADR) price decreased by $2.30, or 2.15%, closing at $104.46 on January 20, 2026 [4]. Group 3: Legal Representation - Pomerantz LLP is investigating claims on behalf of PDD investors and is recognized for its expertise in corporate, securities, and antitrust class litigation [1][5].

Core Viewpoint - A class action lawsuit has been filed against Klarna Group PLC, alleging securities fraud and unlawful business practices by the company and its officers [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline of February 20, 2026, to apply as Lead Plaintiff if they purchased Klarna securities during the Class Period [3]. - The lawsuit follows Klarna's initial public offering (IPO) on September 10, 2025, where 34,311,274 ordinary shares were priced at $40 each [4]. Group 2: Financial Performance and Concerns - Following the IPO, Klarna reported a net loss of $95 million, attributed to increased provisions for credit losses, which rose to $235 million, exceeding analyst estimates of $215.8 million [4]. - Provisions for credit losses represented 0.72% of gross merchandise volume, an increase from 0.44% the previous year [4]. - Klarna's stock price closed at $31.31 per share on December 22, 2025, which is below the IPO price [4]. Group 3: Market and Customer Profile - The company faces scrutiny over customer loan defaults, particularly due to its buy now, pay later (BNPL) business model, which targets younger individuals with lower financial security [4]. - Research from the Richmond Fed indicates that BNPL customers typically have riskier credit profiles, being younger, less-educated, with higher debt burdens and lower credit scores [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Disc Medicine, Inc. and its officers or directors [1] Group 1: Company Overview - Disc Medicine, Inc. is publicly traded on NASDAQ under the ticker symbol IRON [1] - The company is currently facing scrutiny due to a delay in the review timeline of a drug under development, which has raised safety and efficacy concerns flagged by the U.S. Food and Drug Administration [3] Group 2: Stock Performance - Following the news of the FDA's concerns, Disc's stock price experienced a decline of $6.04 per share, representing a 7.84% drop, closing at $71.04 per share on January 15, 2026 [3] Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - A class action lawsuit has been filed against Endeavor Group Holdings, Inc. for alleged securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The class action involves investors who sold Endeavor Class A common stock between January 15, 2025, and March 24, 2025 [4]. - The lawsuit claims that Endeavor and certain officers and directors engaged in a scheme to undermine minority shareholder value while benefiting insiders [4]. - Specific allegations include rejecting a "majority of the minority" vote on a merger, locking in a cash-out merger consideration of $27.50 without contingencies, and disseminating misleading information regarding shareholder fairness [4]. Group 2: Legal Representation - Pomerantz LLP is representing the class in this lawsuit and is recognized for its expertise in corporate, securities, and antitrust class litigation [5]. - Investors are encouraged to contact Pomerantz LLP to join the class action and can obtain a copy of the complaint from their website [2][4].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. for alleged securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The class action lawsuit involves allegations that BellRing and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until March 23, 2026, to request to be appointed as Lead Plaintiff if they purchased BellRing securities during the Class Period [2]. Group 2: Financial Performance and Stock Impact - On May 6, 2025, BellRing disclosed that customers were "hoarding inventory," which would slow sales growth in the third quarter to "low-single-digits," resulting in a stock price drop of $14.88 per share, or 18.97%, closing at $63.55 [4]. - On August 4, 2025, BellRing reported its third-quarter financial results and narrowed its fiscal year 2025 outlook for net sales, leading to a stock price decline of $17.46 per share, or nearly 33%, closing at $36.18 [5].

Core Viewpoint - A class action lawsuit has been filed against Beyond Meat, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from February 27, 2025, to November 11, 2025, seeking damages for misleading statements regarding the company's financial health and operations [1]. Company Overview - Beyond Meat operates in the food industry, focusing on the development, manufacturing, marketing, and sale of plant-based meat products under the "Beyond" brand in the U.S. and internationally [4]. Financial Challenges - Since early 2025, Beyond Meat has faced shrinking demand, increasing debt, and losses, with a primary goal of achieving positive EBITDA by the end of 2026 [5]. - The company has emphasized operational efficiency and cost reduction over revenue growth, which has been deemphasized as a business concern [6]. Allegations of Misleading Statements - The complaint alleges that Defendants made materially false and misleading statements about the company's business and operations, failing to disclose the likelihood of significant asset impairment charges [8]. - It is claimed that the book value of certain long-lived assets exceeded their fair value, which would necessitate a material, non-cash impairment charge [8]. Stock Price Impact - The truth about the company's financial situation began to emerge on October 24, 2025, when Beyond Meat reported expectations of a non-cash impairment charge, leading to a 23.06% drop in stock price [9]. - Subsequent announcements regarding delays in financial reporting and actual impairment charges resulted in further declines in stock price, with a notable loss of $112.3 million reported for Q3 2025, including $77.4 million in non-cash impairment charges [11][12].

Core Viewpoint - Robbins LLP has announced a class action lawsuit against Picard Medical, Inc. for alleged fraudulent stock promotion activities that misled investors [1] Group 1: Allegations Against Picard Medical, Inc. - The lawsuit claims that Picard Medical was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [1] - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [1] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] Group 2: Stock Price Impact - On October 24, 2025, Picard Medical's stock price fell sharply by 70%, dropping to $3.99 per share [1] - Following the initial crash, the stock price has continued to decline, reaching approximately $2.00 per share [1] Group 3: Class Action Participation - Investors who purchased Picard Medical securities between September 2, 2025, and October 31, 2025, may be eligible to participate in the class action [1] - Shareholders wishing to serve as lead plaintiff must file their papers with the court by April 3, 2026 [1] - Participation in the case is not required to be eligible for recovery, allowing investors to remain absent class members if they choose [1]